Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to nutrient intake, stimulating insulin release and suppressing glucagon release. GLP-1 agents demonstrate promising therapeutic efficacy in treating